<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362662">
  <stage>Registered</stage>
  <submitdate>1/08/2012</submitdate>
  <approvaldate>7/08/2012</approvaldate>
  <actrnumber>ACTRN12612000831886</actrnumber>
  <trial_identification>
    <studytitle>A pilot study to investigate the efficacy of dexamphetamine to treat obesity using dosage titration</studytitle>
    <scientifictitle>A pilot study to investigate the efficacy of dexamphetamine to treat obesity using dosage titration</scientifictitle>
    <utrn>U1111-1131-9918</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obesity</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>6 months treatment with dexamphetamine 5mg oral tablets given twice daily. The dose is increased by weekly increments of 10mg  to a maximum of 12 tablets per day (60mg), stopping short of the maximum dose if there are side effects.</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Weight loss from baseline (difference between weight in kg at baseline and weight in kg at 3, 6 and 12 months)</outcome>
      <timepoint>3, 6 and 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Maintenance of weight loss, as determined by change in weight (kg) over the 6 months following cessation of treatment</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>BMI &gt; 30</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unstable heart disease
Uncontrolled hypertension
History of addiction to illicit drugs
uncontrolled epilepsy
weight change of +/- 3kg the past 3 months
breastfeeding, pregnant or planning pregnancy
current depression or other psychiatric illness
current or recent treatment (past 12 months) with psychotropic medication, systemic glucocorticoids or medication for weight loss (eg orlistat)
family history of sudden death from cardiac causes</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>20/06/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Nepean Blue Mountains Local Health District</primarysponsorname>
    <primarysponsoraddress>Nepean Hospital
PO Box 63 
Penrith
NSW 2751</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Nepean Hospital Department of Cardiology Trust Fund</fundingname>
      <fundingaddress>Nepean Hospital, PO Box 63, Penrith, NSW 2751.</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The project is designed to test a) whether dexamphetamine can be used safely to treat adults with obesity, b) whether dexamphetamine is effective for treating obesity over a six month period</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Nepean Blue Mountains Local Health District Human Research Ethics Committee</ethicname>
      <ethicaddress>Nepean Hospital
PO Box 63
Penrith 
NSW 2751</ethicaddress>
      <ethicapprovaldate>12/04/2012</ethicapprovaldate>
      <hrec>12/3 -  HREC/12/NEPEAN/8</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Alison Poulton</name>
      <address>Nepean Hospital
PO Box 63
Penrith
NSW 2751</address>
      <phone>+61 247343366</phone>
      <fax>+61 247341144</fax>
      <email>alison.poulton@sydney.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Alison Poulton</name>
      <address>Nepean Hospital
PO Box 63
Penrith
NSW 2751</address>
      <phone>+61 247343366</phone>
      <fax>+61 247341144</fax>
      <email>alison.poulton@sydney.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Alison Poulton</name>
      <address>Nepean Hospital
PO Box 63
Penrith
NSW 2751</address>
      <phone>+61 247343366</phone>
      <fax>+61 247341144</fax>
      <email>alison.poulton@sydney.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>